[Place of immunotherapy in digestive oncology].

Digestive tumors account for a quarter of all new cancer cases diagnosed worldwide and are responsible for a third of global cancer-related deaths. Immunotherapy with immune checkpoint inhibitors has recently shown its effectiveness in the therapeutic arsenal of these tumors, mainly in the advanced stages. This article summarizes the current indications and the future direction of immunotherapy in patients with digestive malignancies.
Competing Interests: Thibaud Koessler a des mandats de Scientific advisor auprès de Bayer, Lilly, Merck, MSD, Roche, Boehringer Ingelheim. Il a également bénéficié de Travel grants par Lilly, Ipsen et Sanofi. Les autres auteurs n’ont déclaré aucun conflit d’intérêts en relation avec cet article.